Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02707341 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The CorEvitas Psoriasis (PSO) Registry

StatusRecruiting
PhaseNot specified
SponsorCorEvitas
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Enrolling by Invitation → Recruiting
    • Study sites: 0 to 1
    v13
  2. Re-verified, no change to tracked fieldsv12
  3. Eligibility criteria shortened, about 670 words
    • Study title revised
    v11
  4. 2 versions Re-verified since Aug 2, 2021, no change to tracked fieldsv9-v10
  5. Eligibility criteria expanded, about 338 wordsv8
Show 6 earlier versionsHide 6 earlier versions
  1. Eligibility criteria shortened, about 2 wordsv7
  2. Eligibility criteria expanded, about 359 wordsv6
  3. Study description shortened, about 1 wordv5
  4. Eligibility criteria expanded, about 54 words
    • Study title expanded, about 1 word
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Primary endpoint revised
    • Secondary endpoints: 1 to 9
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CorEvitas
24 trials monitored
See all monitored trials
Psoriasis
591 trials monitored
See 24 trials at risk
The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.
Trial Details
NCT Number NCT02707341
Lead Sponsor CorEvitas
Conditions
(from sponsor)		 Psoriasis
Related terms Psoriasis
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov